This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Genor Biopharma Holdings Dirección

Dirección controles de criterios 1/4

Información clave

Feng Guo

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2.4yrs
Participación del CEO	0.3%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	1.1yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Feng Guo (52 yo)

2.4yrs

Permanencia

Dr. Feng Guo Ph D., serves as Chairman of the Board for Genor BioPharma Co., Ltd. since November 2021.He serves as Chairman at Genor Biopharma Holdings Limited since November 02, 2021. Dr. Guo has been th...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Feng Guo	CEO & Chairman	2.4yrs	sin datos	0.29% CN¥ 3.6m
Qibin Liang	Chief Technology Officer	1.7yrs	sin datos	sin datos
Shuhua Han	Chief Scientist	1.7yrs	sin datos	sin datos
Xiaojing Zhu	Vice President of Human Resources	no data	sin datos	sin datos
Tong Li	Chief Medical Officer	2.1yrs	sin datos	sin datos
Cheery Chen	Chief Regulatory Officer	1.7yrs	sin datos	sin datos
Tak Wai Ip	Company Secretary	less than a year	sin datos	sin datos
Huiyang Cheng	Vice President of Global Strategy	2.8yrs	sin datos	sin datos
Jun Lin	Vice President of Quality Analysis	2.7yrs	sin datos	sin datos
Yao Chen	Vice President of Regulatory Affairs	3.2yrs	sin datos	sin datos
Qingtang Duan	General Manager of Yuxi Genor	3.1yrs	sin datos	sin datos
Chengyi Weng	Vice President of Finance	no data	sin datos	sin datos

2.3yrs

Permanencia media

48yo

Promedio de edad

Equipo directivo experimentado: 6998's management team is considered experienced (2.3 years average tenure).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Feng Guo	CEO & Chairman	2.4yrs	sin datos	0.29% CN¥ 3.6m
David J. Kerr	Member of Scientific Advisory Board	less than a year	sin datos	sin datos
Leonard B. Saltz	Member of Scientific Advisory Board	less than a year	sin datos	sin datos
Alex A. Adjei	Member of Scientific Advisory Board	less than a year	sin datos	sin datos
Wen Chen	Independent Non-Executive Director	2.3yrs	sin datos	sin datos
Yu Chen	Non-Executive Director	3.8yrs	sin datos	sin datos
Edwin Fung	Independent Non-Executive Director	2.3yrs	sin datos	sin datos
Honghao Zhou	Independent Non-Executive Director	2yrs	sin datos	sin datos
Dong Lyu	Non Executive Director	less than a year	sin datos	sin datos
Zhijian Chen	Chairman of Scientific Advisory Board	1.3yrs	sin datos	sin datos
Yangxin Fu	Member of Scientific Advisory Board	less than a year	sin datos	sin datos
John F. Seymour	Member of Scientific Advisory Board	less than a year	sin datos	sin datos

1.1yrs

Permanencia media

53yo

Promedio de edad

Junta con experiencia: 6998's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.

This company listing is no longer active

Genor Biopharma Holdings Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Genor Biopharma Holdings Limited Announces Management Changes with Effect from July 29, 2022

Genor Biopharma Holdings Limited Announces Executive Changes

Less than half of directors are independent

Genor Biopharma Holdings Limited Announces Resignation of Zhou Joe Xin Hua as Executive Director and President

Recent updates

Genor Biopharma Holdings Limited Announces Updates on New Product Application Approval of Geptanolimab (GB226) for the Treatment of Relapsed/Refractory Permitting T-Cell Lymphoma

Genor Biopharma Holdings Limited Announces Launch of Phase I/II Clinical Trial of GB263T in China

Genor Biopharma Holdings Limited Announces Launch of Phase I/Ii Clinical Trial Ofgb261 in China

Genor Biopharma Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

Genor Biopharma Holdings Limited Announces Management Changes with Effect from July 29, 2022

Genor Biopharma Holdings Limited Announces Executive Changes

Genor Biopharma Holdings Limited Obtains Investigational New Drug Approval from the National Medical Products Administration

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Approval for Phase I/II Clinical Trials of GB261

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Approval for Phase I/II Clinical Trials of GB261

Genor Biopharma Holdings Limited Announces First Patient Dosed in the First-In-Humanclinical Trial of GB263T

Less than half of directors are independent

Genor Biopharma Holdings Limited Announces Resignation of Zhou Joe Xin Hua as Executive Director and President

Genor Biopharma Holdings Limited Announces First-In-Human Clinical Trial of GB263T Approval by the Bellberry Human Research Ethics Committee

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Drug Application Approval for GB242 (Infliximab)

Genor Biopharma Holdings Limited Announces First Patient Enrolled in the Phase III Clinical Trial of Gb491 in China

JHBP (CY) Holdings Limited Receives Investigational New Drug Approval for GB492 by National Medical Products Administration

Non-Executive Director has left the company

Full year 2020 earnings released: CN¥12.36 loss per share (vs CN¥0.94 loss in FY 2019)

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad